"Health Beyond Boundaries"

"Learn More About Our Products"

Intermediates

API

Finished Products

" Our Strategy"

Our First Strategy
Quality-oriented Product Development

Our Second Strategy
Export-oriented Market Development

Our Third Strategy
Profit-oriented Efficient Production

Download Catalog
Our Products

Research and Development

Research and Development (R&D) in Parand Darou

The Research and Development department of Parand Darou Pharmaceutical Company focuses on the development of both Narcotic and Non-Narcotic Active Pharmaceutical Ingredients (APIs) as well as the development of Finished Dosage Forms (FDFs). The department...

Our Company

As a knowledge-based company, Parand Darou pharmaceutical company started its activity in 2006 producing Narcotic and non- Narcotic APIs such as Codeine Phosphate, Noscapine, Thebaine, Papaverine and Oxycodone. Parand Darou is the second company in the private sector received the Narcotic license from Iran Food and Drug Organization. Meeting the needs of domestic market, Parand Darou exported the products to the Global markets as well.

Parand Darou Pharmaceutical News & Updates

Dr. Yahya Mirzaei has appointed as the New CEO of Parand Darou

Dr. Yahya Mirzaei has appointed as the New CEO of Parand Darou Dr. Yahya Mirzaei has been appointed as the Chief Executive Officer of Parand Darou by decree of Engineer Behzad Mohammadi, CEO of Kimia Group Dr. Mirzaei holds Ph.D. in Organic Chemistry and MBA with in Strategic Management. He brings with himself over 23 years of management experience in pharmaceutical...

Pharmaceutical News & Updates from Iran and the World

FDA approves first new antibiotics to treat gonorrhea in decades, with hope to combat drug resistance

FDA approves first new antibiotics to treat gonorrhea in decades, with hope to combat drug resistance  The U.S. health regulator on Friday approved Innoviva’s oral antibiotic to treat gonorrhea, a common sexually transmitted infection, offering patients an alternative to an injectable drug that was the only recommended treatment until now. The Food and Drug Administration’s approval of the drug, branded as Nuzolvence, addresses a growing public health crisis as gonorrhea has...